Evidence map›Paper›PMID 40093977›Full record

ArticleTherapeutic advances in medical oncology2025

Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.

Fumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, Hiroshige Yoshioka, Eisaku Miyauchi, Kiichiro Ninomiya, Yasunori Murata, Masafumi Takeshita, Masafumi Yamaguchi, Shunichi Sugawara and 31 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Fumihiko KinoshitaDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-4557-0491
Shigeru TanzawaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Toshihiro MisumiDepartment of Data Science, National Cancer Center Hospital East, Chiba, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.ORCID https://orcid.org/0000-0001-7724-0481
Eisaku MiyauchiDepartment of Respiratory Medicine, Tohoku University Hospital, Miyagi, Japan.
Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
Yasunori MurataDepartment of Respiratory Medicine, Ichinomiya Nishi Hospital, Aichi, Japan.
Masafumi TakeshitaDepartment of Respiratory Medicine, Ichinomiya Nishi Hospital, Aichi, Japan.
Masafumi YamaguchiDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Yosuke KawashimaDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kazuki HashimotoDepartment of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.
Masahide MoriDepartment of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.
Akihiko MiyanagaDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2026-9181
Anna HayashiDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Hisashi TanakaDepartment of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Ryoichi HondaDepartment of Respiratory Medicine, Asahi General Hospital, Chiba, Japan.
Masafumi NojiriDepartment of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Yuki SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.
Ken YamamotoDivision of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Hyogo, Japan.
Ken MasudaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Toshiyuki KozukiDepartment of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, Ehime, Japan.
Takahisa KawamuraDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Takuji SuzukiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Teppei YamaguchiDepartment of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Kazuhiro AsadaDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
Satoshi TetsumotoDepartment of Respiratory Medicine and Clinical Immunology, Suita Municipal Hospital, Osaka, Japan.
Hiroshi TanakaDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Satoshi WatanabeDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.ORCID https://orcid.org/0000-0003-0041-6981
Yukihiro UmedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Kakuhiro YamaguchiDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Shoichi KuyamaDepartment of Respiratory medicine, NHO Iwakuni Clinical Center, Yamaguchi, Japan.
Kosuke TsurunoDepartment of Respiratory Medicine, Iizuka Hospital, Fukuoka, Japan.
Yuki MisumiDepartment of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Hiroshi KuraishiDepartment of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan.
Ken YoshiharaDivision of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Shimane, Japan.
Akira NakaoDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Akihito KuboDepartment of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Aichi, Japan.
Toshihiko YokoyamaDepartment of Respiratory Medicine, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, Japan.
Kana WatanabeDepartment of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan.
Nobuhiko SekiDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Skin disorders are major adverse events associated with necitumumab plus gemcitabine and cisplatin (Neci + GC) administration. However, the prognostic effect of skin disorders in patients with lung squamous cell carcinoma (LSCC) administered Neci + GC is unclear. Objectives: We examined this prognostic effect in patients with LSCC, and the usefulness of minocycline administration. Design: This was a sub-analysis of the retrospective multicenter NINJA study. Methods: We performed a landmark survival analysis according to the presence of skin disorders at Day 30 of treatment and examined the usefulness of minocycline for treating skin disorders. Results: Among the 93 patients, 62 (66.7%) had a skin disorder at Day 30. Nineteen, 30, and 13 patients experienced Grade 1, 2, and 3 skin disorders, respectively. The overall survival (OS) and progression-free survival (PFS) of patients with skin disorders at Day 30 were longer than those of patients without skin disorders (median OS: 434 vs 278 days, Conclusion: A skin disorder within 30 days was a favorable prognostic factor for patients with LSCC administered Neci + GC. Additionally, minocycline administration may be beneficial in patients who develop skin disorders within 30 days.

Indexed as

adverse eventlung cancernecitumumabskin disordersquamous cell carcinoma

Identifiers

PMID40093977
PMCPMC11909677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.